Therapy News and Research

RSS

'Targeted' drugs may be effective against lung and colorectal tumors driven by novel gene abnormalities

Novel gene abnormalities discovered in a subpopulation of lung and colorectal tumors could potentially identify patients with a good chance of responding to highly specific "targeted" drugs already in use for treating other cancers, scientists report.

14 Feb 2012

Abbott's Tacrolimus assay provides consistent medication monitoring for organ transplant patients

A new study published in the journal Clinical Chemistry reported Abbott's ARCHITECT Tacrolimus assay provides accurate and consistent medication monitoring for patients taking tacrolimus, an immunosuppressive medication, after receiving solid organ transplantation.

14 Feb 2012

Prevention and treatment options are improving long-term outcomes for heart failure

"Despite the increasing number of people affected, the prognosis for patients with heart failure has steadily improved," said Gregg C. Fonarow, M.D, chairman of American Heart Association Hospital Accreditation Science Committee and professor of cardiovascular medicine of the University of California, Los Angeles.

14 Feb 2012

Radiation treatment transforms breast cancer stem cells into new iBCSCs

Breast cancer stem cells are thought to be the sole source of tumor recurrence and are known to be resistant to radiation therapy and don't respond well to chemotherapy.

14 Feb 2012

Ensysce announces latest data on delivery platform for therapeutic siRNA

Ensysce Biosciences Inc. announced today the publication of their latest data on their delivery platform for short interfering RNA (siRNA) for therapeutic purposes in the journal Materials.

14 Feb 2012

Promising compound may counteract HIV's ability to hijack CD59 protein

One of the frustrations for scientists working on HIV/AIDS treatments has been the human immunodeficiency virus' ability to evade the body's immune system. Now an Indiana University researcher has discovered a compound that could help put the immune system back in the hunt.

14 Feb 2012

New potential therapy for Huntington disease

Medical researchers at the University of Alberta have discovered a promising new therapy for Huntington disease that restores lost motor skills and may delay or stop the progression of the disease based on lab model tests, says the lead researcher.

14 Feb 2012

UT Southwestern installs new system to deliver precise radiation therapy

UT Southwestern Medical Center has installed a new system to deliver extremely precise and individualized radiation treatment, assuring that cancer patients in the region have access to the latest advances in radiation oncology.

14 Feb 2012

Scientists create new mouse model for medulloblastoma

Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) developed a new mouse model for studying a devastating childhood brain cancer called medulloblastoma.

14 Feb 2012

Two studies demonstrate preliminary success of CyBorD in AL amyloidosis

Two studies published today in Blood, the Journal of the American Society of Hematology (ASH), demonstrate preliminary success of an effective multiple myeloma (MM) regimen in patients with AL amyloidosis, a rare and devastating blood disease that results in deposition of damaging abnormal protein in critical organs of the body, including the kidneys, heart, liver, and intestines, and shares some characteristics with MM.

14 Feb 2012

WHI program improves depression-related work disruption

A work-focused, telephone counseling program for depressed employees not only improves depression but also leads to increased productivity and decreased costs, reports a study in the February Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine.

14 Feb 2012

FDA accepts Gilead's Truvada sNDA and grants Priority Review

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults.

14 Feb 2012

Compound makes imipenem 16 times more effective against antibiotic-resistant K. pneumoniae

North Carolina State University chemists have created a compound that makes existing antibiotics 16 times more effective against recently discovered antibiotic-resistant "superbugs."

14 Feb 2012

Two novel devices can predict women at risk of premature birth

Scientists and doctors from the University of Sheffield are developing two novel devices that could lead to the improved prediction of premature births.

14 Feb 2012

Medtronic begins two Symplicity renal denervation system clinical initiatives

Medtronic, Inc. announced today the start of two clinical initiatives evaluating the broader, real-world clinical use of the company's Symplicity renal denervation system across multiple conditions.

From Medtronic 13 Feb 2012

Scientists test new 'therapeutic vaccine' against HIV on volunteers

Scientists from the Antwerp Institute of Tropical Medicine, Antwerp University Hospital and Antwerp University have tested a new 'therapeutic vaccine' against HIV on volunteers. The participants were so to say vaccinated with their own cells.

13 Feb 2012

Starving HIV virus could be the basis for future therapy: Study

In a medical breakthrough researchers at NYU Langone Medical Center and colleagues have shown how some cells in the body can repel attacks from HIV by starving the virus of the building blocks of life.

13 Feb 2012

Tenofovir associated with significant risk of kidney damage and chronic kidney disease

Tenofovir, one of the most effective and commonly prescribed antiretroviral medications for HIV/AIDS, is associated with a significant risk of kidney damage and chronic kidney disease that increases over time, according to a study of more than 10,000 patients led by researchers at the San Francisco VA Medical Center and the University of California, San Francisco (UCSF).

13 Feb 2012

Discovery of novel rearrangements and fusions supports role for NGS in treatment of cancer

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer gene analysis to routine clinical care, and Dana-Farber Cancer Institute today announced the Nature Medicine publication of results from their collaborative next-generation sequencing (NGS) study to assay cancer-relevant genes in 24 non-small cell lung cancer (NSCLC) and 40 colorectal cancer (CRC) cases.

13 Feb 2012

Tiltan initiates TL-118 Phase 2 clinical trial for pancreatic cancer

Tiltan Pharma Ltd. today announced that it has commenced a Phase 2 clinical trial of its anti-angiogenic product TL-118 for the treatment of pancreatic cancer.

13 Feb 2012